A meta-analysis of hemoglobin target for anemia of patients with chronic kidney disease

Jing ZHOU,Wei-jie YUAN
DOI: https://doi.org/10.3760/cma.j.issn.1001-7097.2012.10.006
2012-01-01
Abstract:Objective To explore the role of hemoglobin (Hb) level in mortality and morbidity of chronic kidney disease (CKD)patients,aiming to give some evidence for therapy of anemia.Methods Randomized,clinical trials (RCTs) were identified by searching Medline,Embase and the Cochrane library.All the analyses were performed using the Revman software available free from the Cochrane collaboration.Results Twenty-three trials involving 10 204 patients were identified.Overall,the high Hb target was associated with increased risk of all-cause mortality (RR=1.10,95% CI 1.00 to 1.21),hypertension (RR=1.40,95% CI 1.12 to 1.75),stroke and hospitalization (RR=1.07,95% CI 1.00 to 1.14) compared with low Hb target (P<0.05).No significant difference was found in the risks of non-fatal mycardial infarction (RR=1.13,95% CI 0.79 to 1.62) and renal replacement therapy (RR =1.00,95% CI 0.85 to 1.18).Conclusions Targeting low Hb target is beneficial to CKD patients based on reduced risk of hypertension,hospitalization,stroke and all-cause mortality.However,no significant difference is found in non-fatal mycardial infarction and renal replacement therapy.
What problem does this paper attempt to address?